SlideShare a Scribd company logo
1 of 34
MULTIPLE
SCLEROSIS
Presented by : Abhishek Yadav
M Sc Nursing 1st year.
OUTLINES
• Introduction.
• Definition.
• Incidence.
• Etiology and Risk factors.
• Pathophysiology.
• Clinical Manifestations.
• Diagnostic Evaluation.
• Management.
INTRODUCTION
The autoimmune disorders of nervous
system can attack the CNS which include
brain and spinal cord ,or PNS consisting of
nerves that connect the CNS.
Autoimmune nervous system disorders
include Multiple sclerosis, Myasthenia
gravis, and Guillain- barre syndrome.
DEFINITION
Multiple sclerosis (MS) is a chronic demyelinating
disease that affects the myelin sheath of neurons
in the CNS.
INCIDENCE
• Onset occurs between 20-40 years of age.
• Women are more affected than men.
(AANN,2011).
• Whites are more affected than Hispanics , blacks ,
or Asians .
• Most prevalent in colder climates of North America
& Europe.
• Migration.
ETIOLOGY & RISK FACTORS
• Exact cause is not known yet.
• Most theories suggest that MS is an
immunogenetic viral disease (with Epstein Barr
virus).
• Risk factors are:
– Age ( most of the time between 20-40 yrs).
– Sex (women have more chance).
– Family history (genetic susceptibility).
– Certain infections ( like Epsteinbarr virus).
Continued risk factors…
– Climate (more in cold climate areas).
– Certain auto-immune diseases (higher risks with
thyroid disease, type-1 DM or IBD).
– Smoking.
– Stress, fatigue.
– Physical injury.
– Pregnancy (may relating to stress to labour, or
puerperium).
PATHOPHYSIOLOGY
Due to etiological factors
Activated T-cells (which recognise self Ag) expressed in CNS, &
Macrophages (B-cells) enters the brain from peripherral circulation
Production of inflammatory cytokines & reactive O2 species
Inflammation
Then activated T-cells & B-cells cause
demyelination and destruction of oligodendrocytes
Formation of plaque
Causes scarring & destruction of sheath
Compensatory system starts causing subsidation of edema & inflammation
After that some remyelination process occurs which is often incomplete
Multiple sclerosis.
CLINICAL MANIFESTATIONS
• The course of illness varies from person to
person.
The 4 clinical patterns (types) have been identified:-
1. Relapsing – remitting MS (most common
initial pattern):
Episodes of acute worsening with recovery
and a stable course between relapses.
2. Primary progressive MS:
Gradual, nearly continuous neurologic
deterioration from onset of manifestations.
3. Secondary progressive MS:
Gradual neurologic deterioration with or
without superimposed acute relapses in a
client who previously had relapsing remiting
MS.
4. Progressive relapsing MS:
Gradual neurologic deterioration from the
onset of manifestations but with sub-sequent
superimposed relapses.
The other symptoms are:-
Cerebellar sign:
– Nystagmus
– Ataxia
– Dysarthria
– dysphagia
Motor:
– weakness or paralysis of limbs , trunk or head
– Diplopia
– Scanning speech
– Spasticity of muscles that are chronically affected.
 Sensory:
– Numbness , tingling and other parasthesias
– Patchy blindness (scotomas)
– Blurred vision
– Vertigo, tinnitus,decreased hearing, chronic
neuropathic pain
– Radicular (nerve root) pain in lower thoracic
abdominal region.
– Lhermitte’ s sign is a transient sensory symptom
described as an electric shock radiating down the
spine or into limbs with flexion of neck.
Emotional problems:
– Fatigue (associated with energy needs)
– Depression
– Deconditioning
– Medication side effects.
DIAGNOSTIC EVALUATION
• There is no definitive test for MS.
• Detailed history of episodes of neurologic
dysfunction
• Physical examination.
Continued…
• Other tests include:-
– CSF evaluation (for presence of IgG antibody or
oligoclonal bonding)
– Evoked potentials of optic pathways & auditory
system to assess presence of slowed nerve
conduction.
– MRI of brain and spinal cord (to determine the
presence of MS plaques)
– CT scan ( to detect areas of demyelination , but
with less detail as by MRI).
MEDICAL MANAGEMENT
• No exact cure.
• Aim is to prevent or postpone the long term
disability (often evolves slowly over many
years).
• The treatment falls into 3 categories:-
1. Treatment of acute relapses.
2. Treatment aimed at disease management.
3. Symptomatic treatment.
1. Treatment of acute relapse:-
 Corticosteroid therapy ( anti-inflammatory &
immunosupressive
property )
For example:
 Methyl-prednisolone , (given I.V. or orally)
 Azathioprine & cyclophosphamide (in severe
cases)
2. Treat exacerbations:-
(treatment aimed at disease management)
 Interferon-Beta 1b
- Betaseron, given subcutaneously.
(antiviral & immuno-regulatory)
(for ambulatory clients with relapsing –remitting).
 Interferon Beta 1a
- Avonex,
(for treating replasing form of MS).
Glatiramer acetate
- Copaxane ,
(for relapsing re-emitting MS).
3. Symptomatic treatment:-
 For bladder dysfunction:
- oxybutynin, propantheline.
 For constipation:
- psyllium hydrophilic mucilloid,
suppositories.
 For fatigue:
- amantadine, modafinil .
 For spasticity:
- baclofen, diazefen, dantrolone.
For Tremor :
- propanolol, phenobarbital, clonazepam.
For dysesthesias & trigeminal neurolgia:
- carbamazepine, phenytoin, amitriptyline.
For dysesthesias:
- Transcutaneous electrical nerve stimulation
(TENS) is also helpful.
4. Nutritional therapy:-
- megavitamin therapy (cobalamin/vit. B12
and vit. C )
- low fat diet.
- high roughage diet (to relieve constipation)
5. Other therapies:-
(to improve neurological functioning)
Physical and speech therapies.
Exercise.
Water exercise.
SURGICAL MANAGEMENT
• Deep brain stimulation:-
if other options have failed then a device is
implanted that stimulates an area of brain. (in
case of severe tremor in limbs).
• Implantation of a drug catheter or pump:
a catheter is placed in lower spinal area to
deliver a constant flow of drug like baclofen.
(in case of severe pain or spasticity).
NURSING MANAGEMENT
1. Nursing diagnosis:
Impaired urinary elimination pattern related to
bladder dysfunction as evidenced by low output
and acute pain.
Intervention:
• Assess the skin for incontinance associated
dermatitis with each voiding.
• Maintain fluid intake of 2000ml /day.
• Toilet every 2 hour .
• Scan bladder for post void residual volume.
• If PVR is more than 100ml , then catheterize.
2. Nursing diagnosis:
Impaired elimination pattern related to
immobility & demyelination as evidenced by
disturbed bowel movement.
Intervention:
• Assess for normal bowel movement .
• Administer suppository as adviced by
physician.
• Teach client to consume high fibre diet and
2000 ml of fluid.
3. Nursing diagnosis:
Fatigue related to increased energy needs as
evidenced by facial expression of client.
Intervention:
• Keep the environment cool.
• Provide mental support.
• Plan for rest periods during the day.
• Facilitate sleep by reducing night time
interruption, noise, and light.
4. Nursing diagnosis:
Impaired physical mobility related to weakness,
contractures, spasticity and ataxia as evidenced
by pain in muscles and verbal experience.
Intervention:
• Assess the degree of muscle spasticity.
• Stretch muscles & perform ROM exercise.
• Administer anti-spasmotics as ordered.
• Position in neutral alignment.
• Consult with doctor for splints.
5. Nursing diagnosis:
Situational self esteeem, related to loss of
independence and fear of disability as evidenced
by irritativeness and facial expressions.
Intervention:
• Assess for depression and any related treatment.
• Assess for client’s problem solving strategies.
• Evaluate client’s support system.
• Provide experience that increase the client’
autonomy.
SUMMARY
• Introduction.
• Definition.
• Incidence.
• Etiology and Risk factors.
• Pathophysiology.
• Clinical Manifestations.
• Diagnostic Evaluation.
• Management (medical, surgical & nursing)
REFERENCES
• JOYCE M BLACK, A Textbook of Medical Surgical
Nursing, 2nd volume, 8th Edition, Sounders
Elsevier Publication, P.P. 1909-1914.
• BRUNNER & SUDDARTH’S , A Textbook of Medical
Surgical nursing, 2nd Volume, 13th Edition, Wolters
Kluwer Publication,P.P. 2033-2040.
• http://:www.emedicinehealth.com
• http://:www.dragysmultiplesclerosis.com
• http://:www.ncbi.nlm.nih.gov/pmc/
THANKYOU

More Related Content

What's hot

What's hot (20)

Spinal injury ppt
Spinal injury pptSpinal injury ppt
Spinal injury ppt
 
Ataxia
AtaxiaAtaxia
Ataxia
 
Quadriplegia & Paraplegia
Quadriplegia & ParaplegiaQuadriplegia & Paraplegia
Quadriplegia & Paraplegia
 
Transverse myelitis
Transverse myelitisTransverse myelitis
Transverse myelitis
 
Movement disorder - HUNTINGTON'S DISEASE(Chorea)
Movement disorder - HUNTINGTON'S DISEASE(Chorea)   Movement disorder - HUNTINGTON'S DISEASE(Chorea)
Movement disorder - HUNTINGTON'S DISEASE(Chorea)
 
Encephalitis
EncephalitisEncephalitis
Encephalitis
 
Parkinson diseases
Parkinson diseasesParkinson diseases
Parkinson diseases
 
Encephalitis
EncephalitisEncephalitis
Encephalitis
 
Rehabilitation for paraplegia and quadriplegia
Rehabilitation for paraplegia and quadriplegiaRehabilitation for paraplegia and quadriplegia
Rehabilitation for paraplegia and quadriplegia
 
Myasthenia Gravis
Myasthenia GravisMyasthenia Gravis
Myasthenia Gravis
 
Dementia
DementiaDementia
Dementia
 
Seizures
SeizuresSeizures
Seizures
 
Chorea
Chorea Chorea
Chorea
 
Brain abscess
Brain abscessBrain abscess
Brain abscess
 
Meningitis
MeningitisMeningitis
Meningitis
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Hydrocephalus
HydrocephalusHydrocephalus
Hydrocephalus
 
Meningitis.ppt
Meningitis.pptMeningitis.ppt
Meningitis.ppt
 
Spinal cord tumors
Spinal cord tumorsSpinal cord tumors
Spinal cord tumors
 
Peripheral Neuropathy
Peripheral NeuropathyPeripheral Neuropathy
Peripheral Neuropathy
 

Similar to Multiple sclerosis

Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
Reynel Dan
 

Similar to Multiple sclerosis (20)

Ms
MsMs
Ms
 
multiple sclerosis_063233.pptx
multiple sclerosis_063233.pptxmultiple sclerosis_063233.pptx
multiple sclerosis_063233.pptx
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple Sclerosis
Multiple SclerosisMultiple Sclerosis
Multiple Sclerosis
 
Gullian barrie syndrome (gbs)
Gullian barrie syndrome (gbs)Gullian barrie syndrome (gbs)
Gullian barrie syndrome (gbs)
 
Multiple sclerosis (ms)
Multiple sclerosis (ms) Multiple sclerosis (ms)
Multiple sclerosis (ms)
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple sclerosis 2015
Multiple sclerosis 2015 Multiple sclerosis 2015
Multiple sclerosis 2015
 
Neuromuscular Diseases medicine Seminar.pptx
Neuromuscular Diseases medicine Seminar.pptxNeuromuscular Diseases medicine Seminar.pptx
Neuromuscular Diseases medicine Seminar.pptx
 
Gullian Barre Syndrome.pptx
Gullian Barre Syndrome.pptxGullian Barre Syndrome.pptx
Gullian Barre Syndrome.pptx
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
GB syndrome_015823.pptx
GB syndrome_015823.pptxGB syndrome_015823.pptx
GB syndrome_015823.pptx
 
Pheripheral neuropathy
Pheripheral neuropathyPheripheral neuropathy
Pheripheral neuropathy
 
EPILEPSY
EPILEPSYEPILEPSY
EPILEPSY
 
Anticonvulsives
AnticonvulsivesAnticonvulsives
Anticonvulsives
 
Seizure: Status Epilepticus
Seizure: Status EpilepticusSeizure: Status Epilepticus
Seizure: Status Epilepticus
 
Gullian barr syndrome
Gullian barr syndromeGullian barr syndrome
Gullian barr syndrome
 
Epilepsy recent classification and definitions, dr. amit vatkar, pedaitric ne...
Epilepsy recent classification and definitions, dr. amit vatkar, pedaitric ne...Epilepsy recent classification and definitions, dr. amit vatkar, pedaitric ne...
Epilepsy recent classification and definitions, dr. amit vatkar, pedaitric ne...
 
Guillian barre syndrome
Guillian barre syndromeGuillian barre syndrome
Guillian barre syndrome
 

More from Abhishek Yadav (9)

Geriatric considerations in nursing
Geriatric considerations in nursingGeriatric considerations in nursing
Geriatric considerations in nursing
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Seizure disorders
Seizure disordersSeizure disorders
Seizure disorders
 
Organophosphorus poisoning
Organophosphorus poisoningOrganophosphorus poisoning
Organophosphorus poisoning
 
Leukemias
LeukemiasLeukemias
Leukemias
 
Infertility
InfertilityInfertility
Infertility
 
Congenital & Acquired valvular Heart diseases
Congenital & Acquired valvular Heart diseasesCongenital & Acquired valvular Heart diseases
Congenital & Acquired valvular Heart diseases
 
Assist in application & Removal of plaster cast.
Assist in application & Removal of plaster cast.Assist in application & Removal of plaster cast.
Assist in application & Removal of plaster cast.
 
Fractures
FracturesFractures
Fractures
 

Recently uploaded

Recently uploaded (20)

End Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feelEnd Feel -joint end feel - Normal and Abnormal end feel
End Feel -joint end feel - Normal and Abnormal end feel
 
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. MacklinScleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdfรายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
รายการตํารับยาแผนไทยแห่งชาติ ฉบับ พ.ศ. 2564.pdf
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDFNCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
NCLEX RN REVIEW EXAM CONTENT BLUE BOOK PDF
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...Scientificity and feasibility study of non-invasive central arterial pressure...
Scientificity and feasibility study of non-invasive central arterial pressure...
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRYDEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
 
Creating Accessible Public Health Communications
Creating Accessible Public Health CommunicationsCreating Accessible Public Health Communications
Creating Accessible Public Health Communications
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediatesBMK Glycidic Acid (sodium salt)  CAS 5449-12-7 Pharmaceutical intermediates
BMK Glycidic Acid (sodium salt) CAS 5449-12-7 Pharmaceutical intermediates
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...Relationship between vascular system disfunction, neurofluid flow and Alzheim...
Relationship between vascular system disfunction, neurofluid flow and Alzheim...
 

Multiple sclerosis

  • 1. MULTIPLE SCLEROSIS Presented by : Abhishek Yadav M Sc Nursing 1st year.
  • 2. OUTLINES • Introduction. • Definition. • Incidence. • Etiology and Risk factors. • Pathophysiology. • Clinical Manifestations. • Diagnostic Evaluation. • Management.
  • 3. INTRODUCTION The autoimmune disorders of nervous system can attack the CNS which include brain and spinal cord ,or PNS consisting of nerves that connect the CNS. Autoimmune nervous system disorders include Multiple sclerosis, Myasthenia gravis, and Guillain- barre syndrome.
  • 4. DEFINITION Multiple sclerosis (MS) is a chronic demyelinating disease that affects the myelin sheath of neurons in the CNS.
  • 5.
  • 6. INCIDENCE • Onset occurs between 20-40 years of age. • Women are more affected than men. (AANN,2011). • Whites are more affected than Hispanics , blacks , or Asians . • Most prevalent in colder climates of North America & Europe. • Migration.
  • 7. ETIOLOGY & RISK FACTORS • Exact cause is not known yet. • Most theories suggest that MS is an immunogenetic viral disease (with Epstein Barr virus). • Risk factors are: – Age ( most of the time between 20-40 yrs). – Sex (women have more chance). – Family history (genetic susceptibility). – Certain infections ( like Epsteinbarr virus).
  • 8. Continued risk factors… – Climate (more in cold climate areas). – Certain auto-immune diseases (higher risks with thyroid disease, type-1 DM or IBD). – Smoking. – Stress, fatigue. – Physical injury. – Pregnancy (may relating to stress to labour, or puerperium).
  • 9. PATHOPHYSIOLOGY Due to etiological factors Activated T-cells (which recognise self Ag) expressed in CNS, & Macrophages (B-cells) enters the brain from peripherral circulation Production of inflammatory cytokines & reactive O2 species Inflammation Then activated T-cells & B-cells cause demyelination and destruction of oligodendrocytes Formation of plaque Causes scarring & destruction of sheath Compensatory system starts causing subsidation of edema & inflammation After that some remyelination process occurs which is often incomplete Multiple sclerosis.
  • 10. CLINICAL MANIFESTATIONS • The course of illness varies from person to person. The 4 clinical patterns (types) have been identified:-
  • 11. 1. Relapsing – remitting MS (most common initial pattern): Episodes of acute worsening with recovery and a stable course between relapses.
  • 12. 2. Primary progressive MS: Gradual, nearly continuous neurologic deterioration from onset of manifestations.
  • 13. 3. Secondary progressive MS: Gradual neurologic deterioration with or without superimposed acute relapses in a client who previously had relapsing remiting MS.
  • 14. 4. Progressive relapsing MS: Gradual neurologic deterioration from the onset of manifestations but with sub-sequent superimposed relapses.
  • 15. The other symptoms are:- Cerebellar sign: – Nystagmus – Ataxia – Dysarthria – dysphagia Motor: – weakness or paralysis of limbs , trunk or head – Diplopia – Scanning speech – Spasticity of muscles that are chronically affected.
  • 16.  Sensory: – Numbness , tingling and other parasthesias – Patchy blindness (scotomas) – Blurred vision – Vertigo, tinnitus,decreased hearing, chronic neuropathic pain – Radicular (nerve root) pain in lower thoracic abdominal region. – Lhermitte’ s sign is a transient sensory symptom described as an electric shock radiating down the spine or into limbs with flexion of neck.
  • 17. Emotional problems: – Fatigue (associated with energy needs) – Depression – Deconditioning – Medication side effects.
  • 18. DIAGNOSTIC EVALUATION • There is no definitive test for MS. • Detailed history of episodes of neurologic dysfunction • Physical examination.
  • 19. Continued… • Other tests include:- – CSF evaluation (for presence of IgG antibody or oligoclonal bonding) – Evoked potentials of optic pathways & auditory system to assess presence of slowed nerve conduction. – MRI of brain and spinal cord (to determine the presence of MS plaques) – CT scan ( to detect areas of demyelination , but with less detail as by MRI).
  • 20. MEDICAL MANAGEMENT • No exact cure. • Aim is to prevent or postpone the long term disability (often evolves slowly over many years). • The treatment falls into 3 categories:- 1. Treatment of acute relapses. 2. Treatment aimed at disease management. 3. Symptomatic treatment.
  • 21. 1. Treatment of acute relapse:-  Corticosteroid therapy ( anti-inflammatory & immunosupressive property ) For example:  Methyl-prednisolone , (given I.V. or orally)  Azathioprine & cyclophosphamide (in severe cases)
  • 22. 2. Treat exacerbations:- (treatment aimed at disease management)  Interferon-Beta 1b - Betaseron, given subcutaneously. (antiviral & immuno-regulatory) (for ambulatory clients with relapsing –remitting).  Interferon Beta 1a - Avonex, (for treating replasing form of MS). Glatiramer acetate - Copaxane , (for relapsing re-emitting MS).
  • 23. 3. Symptomatic treatment:-  For bladder dysfunction: - oxybutynin, propantheline.  For constipation: - psyllium hydrophilic mucilloid, suppositories.  For fatigue: - amantadine, modafinil .  For spasticity: - baclofen, diazefen, dantrolone.
  • 24. For Tremor : - propanolol, phenobarbital, clonazepam. For dysesthesias & trigeminal neurolgia: - carbamazepine, phenytoin, amitriptyline. For dysesthesias: - Transcutaneous electrical nerve stimulation (TENS) is also helpful.
  • 25. 4. Nutritional therapy:- - megavitamin therapy (cobalamin/vit. B12 and vit. C ) - low fat diet. - high roughage diet (to relieve constipation) 5. Other therapies:- (to improve neurological functioning) Physical and speech therapies. Exercise. Water exercise.
  • 26. SURGICAL MANAGEMENT • Deep brain stimulation:- if other options have failed then a device is implanted that stimulates an area of brain. (in case of severe tremor in limbs). • Implantation of a drug catheter or pump: a catheter is placed in lower spinal area to deliver a constant flow of drug like baclofen. (in case of severe pain or spasticity).
  • 27. NURSING MANAGEMENT 1. Nursing diagnosis: Impaired urinary elimination pattern related to bladder dysfunction as evidenced by low output and acute pain. Intervention: • Assess the skin for incontinance associated dermatitis with each voiding. • Maintain fluid intake of 2000ml /day. • Toilet every 2 hour . • Scan bladder for post void residual volume. • If PVR is more than 100ml , then catheterize.
  • 28. 2. Nursing diagnosis: Impaired elimination pattern related to immobility & demyelination as evidenced by disturbed bowel movement. Intervention: • Assess for normal bowel movement . • Administer suppository as adviced by physician. • Teach client to consume high fibre diet and 2000 ml of fluid.
  • 29. 3. Nursing diagnosis: Fatigue related to increased energy needs as evidenced by facial expression of client. Intervention: • Keep the environment cool. • Provide mental support. • Plan for rest periods during the day. • Facilitate sleep by reducing night time interruption, noise, and light.
  • 30. 4. Nursing diagnosis: Impaired physical mobility related to weakness, contractures, spasticity and ataxia as evidenced by pain in muscles and verbal experience. Intervention: • Assess the degree of muscle spasticity. • Stretch muscles & perform ROM exercise. • Administer anti-spasmotics as ordered. • Position in neutral alignment. • Consult with doctor for splints.
  • 31. 5. Nursing diagnosis: Situational self esteeem, related to loss of independence and fear of disability as evidenced by irritativeness and facial expressions. Intervention: • Assess for depression and any related treatment. • Assess for client’s problem solving strategies. • Evaluate client’s support system. • Provide experience that increase the client’ autonomy.
  • 32. SUMMARY • Introduction. • Definition. • Incidence. • Etiology and Risk factors. • Pathophysiology. • Clinical Manifestations. • Diagnostic Evaluation. • Management (medical, surgical & nursing)
  • 33. REFERENCES • JOYCE M BLACK, A Textbook of Medical Surgical Nursing, 2nd volume, 8th Edition, Sounders Elsevier Publication, P.P. 1909-1914. • BRUNNER & SUDDARTH’S , A Textbook of Medical Surgical nursing, 2nd Volume, 13th Edition, Wolters Kluwer Publication,P.P. 2033-2040. • http://:www.emedicinehealth.com • http://:www.dragysmultiplesclerosis.com • http://:www.ncbi.nlm.nih.gov/pmc/